First Oral GLP-1 Agonist Showcased while Approval Pending

ADA 2019 ICYMI: Safety and efficacy of oral semaglutide in patients with T2DM was demonstrated in results of 3 PIONEER program clinical trials.   Highlights, here.

Source: ConsultantLive - June 26, 2019 Category: Internal Medicine Authors: Kenneth J. Bender, PharmD, MA Tags: Diabetes Diabetes Type 2 Source Type: news